美股市場個股詳情

SYK 史賽克

添加自選

335.610
-1.540-0.46%

收盤價 04/26 16:00 (美東)

336.010
+0.400+0.12%

盤前 08:00 (美東)

1276.89億總市值40.68市盈率TTM

史賽克股票討論區

登錄發表評論

Moomoo AI

02/09 18:58

The recent insider sale of Stryker shares at the current price is viewed negatively. However, high insider ownership is seen positively, suggesting management's consideration for shareholders. Yet, the absence of insider buying over the past year is worrisome.

Don't Ignore The Insider Selling In Stryker

Moomoo AI

02/02 19:31

The EPS decline doesn't align with share price changes, indicating other factors. Management might be prioritizing revenue growth over EPS. The company's recent performance improvement suggests potential business momentum.

Despite the Downward Trend in Earnings at Stryker (NYSE:SYK) the Stock Climbs 9.4%, Bringing Five-year Gains to 97%

專欄Stryker Shares Surge 6.3% as 2024 Outlook, Q4 Results Beat Estimates

$史賽克(SYK.US)$ shares advanced 6.6% after the company gave a better-than-expected outlook for 2024 and delivered an earnings beat, prompting analysts to upgrade the stock.
The company sees 2024 adjusted earnings to reach $11.70 to $12 a share, according to its press release. That's higher than the $11.54 estimate of analysts polled by Capital IQ, according to MT Newswires.
"Based on our momentum for 2023, strong proce...

編輯精選：在moomoo社群掌握Q4機會！

Moomoo AI

2023/12/31 20:39

Investors feel Stryker's high P/E ratio is justified due to its favorable earnings outlook. Their optimism on consistent earnings growth maintains the elevated ratio as expectations for a drop in earnings are low. A significant change in conditions could alter this supportive investor sentiment.

Investors Still Waiting For A Pull Back In Stryker Corporation (NYSE:SYK)

Analysts Notebook

2023/12/27 18:18

專欄Biotech Outlook 2024: Analysts Believe the Biotech Sector is Poised for Recovery Next Year

Following a turbulent period, there has been a notable change in the trajectory of biotech stocks. After experiencing significant downturns in 2021 and 2022, the $SPDR標普生物科技ETF(XBI.US)$ has seen an increase of 5.5% in the current year. However, it continues to trail considerably behind the$標普500指數(.SPX.US)$, which has achieved a 24% gain. However, analysts indicate that the previously cool sent...

Moomoo AI

2023/12/25 03:28

Baird advocates medtech companies such as Alcon, Stryker, and Cooper due to product and pricing strengths. Belief is strong in Alcon's 2024 margin possibilities, Stryker's premium pricing and predicted robust orthopedic demand, and projected revenue growth for Boston Scientific and Axonics.

Baird Names Top Medtech Picks for 2024; Bullish on Alcon, Axonics

Moomoo AI

2023/12/20 21:21

Stryker has proven its ability to reinvest capital at good rates of return, and with consistency in returns, it can potentially yield favorable share price returns. Despite some risks, this stock is worth further exploration.

Slowing Rates Of Return At Stryker (NYSE:SYK) Leave Little Room For Excitement

Moomoo AI

2023/12/09 22:30

Insiders at Stryker have been selling shares without making any purchases in the past year, a potential red flag despite the company's profitability and growth. The absence of insider purchases raises caution, even though significant insider ownership generally aligns with shareholder interest.

Stryker Insiders Sell US$153m Of Stock, Possibly Signalling Caution

Moomoo AI

2023/10/22 00:25

BofA Securities backs these picks for their great quality, consistent execution, and profitability, leading to quick compounded earnings, despite GLP-1 drugs sector uncertainties. Novo Nordisk's SELECT trial financial figures will be a key aspect in November.

Boston Sci, Stryker, Dexcom, Shockwave Are BoA's Top Medtech Picks

暫無評論

分析

分析師評級

暫無數據

目標價預測

暫無數據

熱議

美股

綜合熱度